Trade Summary

5 days ago, Jamil Khurram, serving as Chief Medical Officer at GALECTIN THERAPEUTICS INC (GALT), sold 52,037 shares at $5.04 per share, for a total transaction value of $262,083.68.

This sale represents a 100.00% decrease in Jamil Khurram's stake in the company. This is considered a high-conviction trade given the significant change in ownership.

The trade was executed on Friday, June 26, 2026 and publicly disclosed via SEC Form 4 filing on Tuesday, June 30, 2026 at 7:23 PM ET, 4 days after the trade was made.

GALECTIN THERAPEUTICS INC operates in the HEALTHCARE sector, specifically within the BIOTECHNOLOGY industry. Insider selling activity in this sector can provide valuable signals about industry trends and company-specific developments.